SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Referencias del artículo

WARLEY, Eduardo et al. Factores asociados al estadio clínico avanzado en el inicio de la terapia antirretroviral. Medicina (B. Aires) [online]. 2012, vol.72, n.5, pp. 367-370. ISSN 0025-7680.

    1. Emery S, Neuhaus JA, Philios AN, et al. [Strategies for Management of Antiretroviral Therapy (SMART) Study Group]. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008; 197: 1133-44. [ Links ]

    2. Sterne JA, May M, Costagliola D, et al. (When to Start Consortium). Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373: 1352-63. [ Links ]

    3. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360: 1815-26. [ Links ]

    4. Funk M, Fusco J, Cole S, et al. HAART initiation and clinical outcomes: insights from the CASCADE cohort of HIV- 1 seroconverters on "when to start". XVIII International AIDS Conference, Vienna, July 18-23, 2010. Abstract THLBB201. [ Links ]

    5. HIV-Casual colaboration. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries. An observational study. Ann Intern Med 2011; 154: 509-15. [ Links ]

    6. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 10, 2011; 1-166. En: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Consultado: 21/09/ 2011. [ Links ]

    7. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society. USA panel. JAMA 2010; 304: 321-33. [ Links ]

    8. Sociedad Argentina de Infectología. Consenso Argentino de Terapia Antirretroviral 2010. En: http://www.sadi.org.ar/recomendaciones.html. Consultado: 21/09/2011. [ Links ]

    9. The Antiretroviral Therapy in Lower Income Countries (ART-LINC) Study Group. Cohort profile: Antiretroviral therapy en lower income countries. International Journal of Epidemiology 2005;34: 979-86. [ Links ]

    10. Zala C, Rustad C, Chan K, et al. Determinants of treatment access in a population-based cohort of HIV-positive men and women living in Argentina. Medscape J Med 2008; 10: 78. [ Links ]

    11. Gardner E, Mc Lees M, Steiner J, Del Río C, Burman W. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 2011; 52: 793-800. [ Links ]

    12. Lange JMA. "Test and Treat": is it enough? Clin Infect Dis 2011; 52: 801-02. [ Links ]

    13. Boletín sobre el VIH/sida en la Argentina. Año XIII. Noviembre 2010. N° 27 En: http://www.msal.gov.ar/sida/pdf/boletines-inves-publi/boletin-12-10.pdf; http://www.msal.gov.ar/sida/pdf/boletines-inves-publi/boletin-12-10.pdf. Consultado 30/10/2010. [ Links ]

    14. Instituto nacional de estadísticas y censo de la República Argentina, Censo 2010. En: http://www.censo2010.indec.gov.ar/. Consultado: 21/9/2011. [ Links ]

    15. Warley E; Shield D; Salas M, et al. Adherencia a las terapias antirretrovirales en una población de bajos recursos económicos de la región suburbana de Buenos Aires. Rev Panam Infectol 2008; 10: 43-7. [ Links ]

    16. Centers for Disease Control. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992; 41: 1-19. [ Links ]

    17. Beltrán M, Gil R, Nasiff V, Sanga N, Loza S. Treinta meses de seguimiento prospectivo del tratamiento antirretroviral combinado en una cohorte hospitalaria de pacientes infectados por el HIV-1 de San isidro, Buenos Aires, Argentina. Actualizaciones en SIDA 2006; 14: 42-6. [ Links ]

    18. Kigozi, I, Dobkin, L, Martin, J, et al. Late-disease stage at presentation to an HIV clinic in the era of free antiretroviral therapy in sub-Saharan Africa. J Acquir Immune Defic Syndr 2009; 52: 280-9. [ Links ]

    19. Warley, E, Tamayo Antabak N , Desse J, et al. Características de la infección por HIV/sida según sexo en una región del Gran Buenos Aires. Períodos 1998-2002/2003- 2005. Medicina (B Aires) 2009; 69: 305-10. [ Links ]

    20. Warley, E, Tamayo Antabak N, Desse J, et al. Desarrollo de neoplasias e infecciones definitorias de SIDA después de iniciar la terapia antirretroviral de alta eficacia. Medicina (B Aires) 2010; 70: 49-52. [ Links ]

    21. Dunkle K, Jewkes R, Brown H, Gray G, McIntryre J, Harlow S. Gender-based violence, relationship power, and risk of HIV infection in women attending antenatal Clinics in South Africa. Lancet 2004; 363: 1415-21. [ Links ]

    22. Xu F, Kilmarx P, Supawitkul S, et al. HIV-1 seroprevalence, risk factors, and preventive behaviors among women in Northern Thailand. J Acquir Immune Defic Syndr 2000; 25: 353-9. [ Links ]

    23. Quinn T, Overbaugh J. HIV/AIDS in women: an expanding epidemic. Science 2005; 308: 1582-3. [ Links ]

    1. Fox W. The problem of self-administration of drugs; with particular reference to pulmonary tuberculosis. Tubercle 1958; 39: 269-74. [ Links ]

    2. Home and sanatorium treatment of pulmonary tuberculosis in South India. Bull Wld Hlth Org 1959; 21: 51-144. [ Links ]

    3. Moodie AS. Mass ambulatory chemotherapy in the treatment of tuberculosis in a predominantly urban community. Am Rev Resp Dis 1967; 95: 384-97. [ Links ]

    4. Canetti G, Grumbach F, Grosset J. Long-term, two-stage chemotherapy of advanced experimental murine tuberculosis with intermittent regimens during the second stage. Tubercle 1963; 44: 236-40. [ Links ]

    5. Tuberculosis Chemotherapy Centre, Madras. A concurrent comparison of intermittent (twice-weekly) isoniazid plus streptomycin and daily isoniazid plus PAS in the domiciliary treatment of pulmonary tuberculosis; Bull Wld Hlth Org 1964; 31: 247-71. [ Links ]

    6. Dickinson JM, Mitchison DA. In vitro studies of the choice of drugs for intermittent chemotherapy of tuberculosis. Tubercle 1966; 47: 236. [ Links ]

    7. Dickinson JM, Ellard GA, Mitchison DA. Suitability of isoniazid and ethambutol for intermittent administration in the treatment of tuberculosis. Tubercle 1968; 49: 351-65. [ Links ]

    8. Dickinson JM, Mitchison DA. Observations in vitro on the suitability of pyrazinamide for intermittent chemotherapy of tuberculosis. Tubercle 1970; 49: 389-96. [ Links ]

    9. Humphries M. Tuberculosis: history of directly observed therapy. The Lancet 1995; 346: 380. [ Links ]

    10. Miceli IP. Quousque tandem?. Tratamiento autoadministrado en tuberculosis. Medicina (B Aires) 2005; 65: 553-6. [ Links ]

    11. British Thoracic and Tuberculosis Association. Short-course chemotherapy in pulmonary tuberculosis. A controlled trial by the British Thoracic and Tuberculosis Association. Lancet 1976; 2: 1102-4. [ Links ]

    12. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 6-month and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong. The results up to 30 months. Am Rev Respir Dis 1977; 115: 727-35. [ Links ]

    13. Hong Kong Chest Service/British Medical Research Council. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1987; 136: 1339-42. [ Links ]

    14. Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in Tuberculosis. N England J Med 1994; 330: 1179-84. [ Links ]

    15. Lago JJ, Bensimón M, Villalba JC, García LB, Callejas D. Tratamiento Supervisado de la Tuberculosis integrado a los Servicios Generales de Salud en la Provincia de Chubut. Actas del XVI Congreso Argentino de Tisiología y Neumonología, p 119-124, Córdoba, Argentina, 1977. [ Links ]

    16. Organización Panamericana de la Salud (OPS). ¿Qué es el DOTS/TAES?. Guía para comprender la estrategia de lucha antituberculosa recomendada por la OMS y conocida como estrategia DOTS/TAES. Washington OPS/OMS, 1; 999: 7. En: http://www.paho.org/spanish/dd/pub/Tuberculosis-55.pdf.; consultado el 19/07/2011. [ Links ]

    17. Administración Nacional de Laboratorios e Institutos de Salud (ANLIS). Programa Nacional de Tuberculosis. Normas Técnicas 2008. En: http://www.anlis.gov.ar/inst/iner/archivos/Normas2008Tuberculosis.pdf; consultado el 19/07/2011. [ Links ]

    18. Administración Nacional de Laboratorios e Institutos de Salud (ANLIS). Tuberculosis. Resultados del tratamiento de la Tuberculosis Pulmonar ED +. República Argentina 1980-2008. En: http://www.anlis.gov.ar/inst/iner/archivos/Resultados_TratamientoTB_08.pdf; consultado el 19/07/2011. [ Links ]

    19. Organización Mundial de la Salud (OMS). Treatment of tuberculosis guidelines for National Programmes, fourth edition, 2010. En: http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf.; consultado el 19/07/2011. [ Links ]

    20. American Thoracic Society. Guidelines for short-course tuberculosis chemotherapy. Am Rev Respir Dis 1980; 121: 611-4. [ Links ]

    21. Organización Mundial de la Salud. Tuberculosis. Proseguir la expansión y mejora de un DOTS de calidad. En: http://www.who.int/tb/dots/es/; consultado el 19/07/2011. [ Links ]

    22. ANLIS, Ministerio de Salud, Presidencia de la Nación. Notificación de casos de tuberculosis en la República Argentina. Período 1980-2009. En: htpp://www/anlis.gov.ar/inst/iner/archivos/NotificaciónTB_09.pdf; consultado el 19/07/2011. [ Links ]

    23. Chirico C, Kuriger A, Fernández H, Morcillo N. Tuberculosis en la Región Sanitaria V de la Provincia de Buenos Aires. Análisis de su tendencia entre 1984 y 1996. Medicina (B Aires) 1999; 59: 332-8. [ Links ]

    24. Chirico C, Kuriger C, Etchavarria M, Casamayor L, Morcillo N. Evaluación del tratamiento antituberculoso en la Zona Norte del conurbano bonaerense. Medicina (B Aires) 2007; 67: 131-5. [ Links ]

    25. Doyle JA, Lambertini A y Dolmann A. Intermittent chemotherapy with three drugs in the treatment of pulmonary tuberculosis. Tubercle 1970; 51: 397-402. [ Links ]

    26. Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis: consensus statement of the public health tuberculosis guidelines panel. JAMA 1998; 279: 943-8. [ Links ]

    27. ATS. An official ATS statement. Hepatotoxicity of antituberculosis theraphy. Am J Crit Care Med 2006; 174: 945-52. [ Links ]

    28. Sharma PK, Balamuruan A, Saha PJ, Pandey RM, Mehra NK. Evaluation of clinical immunogenic risk factors for the development of hepatitis during antituberculosis treatment. Am J Crit Care Med 2002; 166: 916-9. [ Links ]

    29. Study Group on Chemotherapy and Chemoprophylaxis in Tuberculosis Control. WHO tech Rep 1957; 141. [ Links ]

    1. Nimorakiotakis B, Winkel KD. Marine envenomations. Part 1. Jellyfish (Review). Aust Fam Physician 2003; 32: 969-74. [ Links ]

    2. Vera C, Kolbach M, Zegpi MS, Vera F, Lonza JP. Picaduras de medusas: actualización. Rev Med Chil 2004; 132: 233-41. [ Links ]

    3. Bailey P, Little M, Jelinek G, Wilce J. Jellyfish envenoming syndromes: unknown toxic mechanisms and unproven therapies. Med J Aust 2003; 178: 34-7. [ Links ]

    4. En: http://www.perfil.com.ar/ediciones/2012/2/edicion_652/contenidos/noticia_0058.html; consultado el 4/5/2012. [ Links ]

    5. Müller F. Polypen und Quallen von Santa Catharina. Olindias sambaquiensis n.sp. Archiv für Naturgeschichte 1861; 1: 312-9. [ Links ]

    6. Mianzan H, Zamponi M. Estudio bioecológico de Olindias sambaquiensis, Muller 1861 (Limnomedusae, Olindiidae) en el área de Monte Hermoso: factores meteorológicos que favorecen su aparición. Iheringia Sér misc 1988; 2: 63-8. [ Links ]

    7. Macchi GJ, Mianzan H, Christiansen HE, Ramírez F. Hystology of the gonadal cycle of the stinging hydromedusa Olindias sambaquiensis, Muller [1861] at Blanca Bay, Argentina. Bollettino della Societa Adriatica di Scienze 1995; 76: 59-68. [ Links ]

    8. Kokelj F, Mianzan H, Avian M, Burnett JW. Dermatitis due to Olindias sambaquiensis: a case report. Cutis 1993; 51: 339-42. [ Links ]

    9. Burnett JW, Calton GJ. Venomous pelagic coelenterates: Chemistry, toxicology, inmunology and treatment of their stings (Review). Toxicon 1987; 25: 581-602. [ Links ]

    10. Haddad V Jr, da Silveira FL, Cardoso JL, Morandini AC. A report of 49 cases of cnidarian envenoming from southeastern Brazilian coastal waters. Toxicon 2002; 40: 1445-50. [ Links ]

    11. Haddad V Jr, da Silveira FL, Migotto AE. Skin lesions in envenoming by cnidarians (Portuguese man-of-war and jellyfish): etiology and severity of accidents on the Brazilian coast. Rev Inst Med Trop Sao Paulo 2010; 52: 47-50. [ Links ]

    12. Resgalla C, Rosseto AL, Haddad V. Report of an outbreak of sting caused by Olindias sambaquiensis Muller, 1861 (Cnidaria: Hydrozoa) in Southern Brazil. Brazilian Journal of Oceanography 2011; 59: 391-6. [ Links ]

    13. Burnett JW, Calton GJ, Burnett HW. Jellyfish envenomation syndromes (Review). J Am Acad Dermatol 1986; 14: 100-6. [ Links ]

    14. Singletary EM, Rochman AS, Bodmer JC, Holstege CP. Envenomations (Review). Med Clin North Am 2005; 89: 1195-224. [ Links ]

    15. Currie BJ. Snakes, jellyfish and spiders (Review). Adv Exp Med Biol 2008; 609: 43-52. [ Links ]

    16. Wong D, Meiking T, Rosen L, Taplin D, Hogan D, Burnett J. Seabather's eruption. Clinical, histologic, and immunologic features. J Am Acad Dermatol 1994; 30: 399-406. [ Links ]

    17. Greenland P, Hutchinson D, Park T. Irukandji Syndrome: what nurses need to know (Review). Nurs Health Sci 2006; 8: 66-70. [ Links ]

    18. Ottuso PT. Aquatic antagonists: Cubozoan jellyfish (Chironex fleckeri and Carukia barnesi) (Review). Cutis 2010; 85: 133-6. [ Links ]

    19. Auerbach P, Hays J. Erythema nodosum following a jellyfish sting. J Emerg Med 1987; 5: 487-91. [ Links ]

    20. Burke W. Cnidarians and human skin. Dermatologic Therapy 2002; 15: 18-25. [ Links ]

    21. Kokelj F, Stinco G, Avian M, Mianzan H, Burnett JW. Cell-mediated sensitization to jellyfish antigens confirmed by positive patch tests to Olindias sambaquiensis preparations. J Am Acad Dermatol 1995; 33: 307-9. [ Links ]

    22. Finn BC, Young P, Bruetman JE. Takotsubo, discinesia apical transitoria. Presentación de cuatro casos y revisión de la literatura. Medicina (B Aires) 2005; 65: 415-8. [ Links ]

    23. Arnold JJ, Williams PM. Anaphylaxis: recognition and management (Review). Am Fam Physician 2011; 84: 1111-8. [ Links ]

    24. Hartwick RJ, Callanan V, Williamson JAH. Disarming the box jellyfish: nematocyst inhibition in Chironex fleckeri. Med J Aust 1980; 1: 15-20. [ Links ]

    25. Mianzan HW, Fenner PJ, Cornelius PF, Ramírez FC. Vinegar as a disarming agent to prevent further discharge of the nematocysts of the stinging hydromedusa Olindias sambaquiensis. Cutis 2001; 68: 45-8. [ Links ]

    26. Exton D, Fenner P, Williamson J. Cold packs: effective topical analgesia in the treatment of painful stings by Physalia and other jellyfish. Med J Aust 1989; 151: 625-6. [ Links ]

    27. Carrette TJ, Cullen P, Little M, Peiera PL, Seymour JE. Temperature effects on box jellyfish venom: a possible treatment for envenomed patients? Med J Aust 2002; 177: 654-5. [ Links ]

    28. Taylor JG. Treatment of jellyfish stings. Med J Aust 2007; 186: 43. [ Links ]

    29. Loten C, Stokes B, Worsley D, Seymour JE, Jiang S, Isbister GK. A randomized controlled trial of hot water (45°C) immersion versus ice packs for pain relief in bluebottle stings. Med J Aust 2006; 184: 329-33. [ Links ]

    1. Azziz R. PCOS: A diagnostic challenge. Reprod Biomed Online 2004; 6: 644-8. [ Links ]

    2. Abbott DH, Dumesic DA, Franks S. Developmental origin of polycystic ovary syndrome - a hypothesis. J Endocrinol 2002; 174: 1-5. [ Links ]

    3. Franks S. Polycystic ovary syndrome. New Engl J Med 1995; 333: 853- 61. [ Links ]

    4. Azziz R, Dumesic DA, Goodarzi MO. Polycystic ovary syndrome: an ancient disorder? Fertil Steril 2011; 95: 1544-8. [ Links ]

    5. Zegher F, Ibañez L. Prenatal growth restraint followed by catch-up of weight: a hyperinsulinemic pathway to polycystic ovary syndrome. Fertil Steril 2006; 86: 4-5. [ Links ]

    6. Ong KK, Dunger DB. Birth weight, infant growth and insulin resistance. Eur J Endocrinol 2004; 151: 131-9. [ Links ]

    7. Martı-Henneberg C, Vizmanos B. The duration of puberty in girls is related to the timing of its onset. J Pediatr 1997; 131: 618-21. [ Links ]

    8. Kirchengast S, Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod 2001; 16: 1255-60. [ Links ]

    9. Hong Y, Yang D, Liu W, et al. Dyslipidemia in relation to body mass index and insulin resistance in Chinese women with polycystic ovary syndrome. J Biol Regul Homeost Agents. 2011; 25: 365-74. [ Links ]

    10. Wild RA. Dyslipidemia in PCOS. Steroids. 2012; 77: 295-9. [ Links ]

    11. Padmanabhan V, Veiga-Lopez A, Abbott DH, et al. Developmental programming: impact of prenatal testosterone excess and postnatal weight gain on insulin sensitivity index and transfer of traits to offspring of overweight females. Endocrinology 2010; 151: 595-605. [ Links ]

    12. Nisenblat V, Norman RJ. Androgens and polycystic ovary syndrome. Curr Opin Endocrinol Diabetes Obes 2009; 16: 224-31. [ Links ]

    13. Wu XY, Li ZL, Wu CY, et al. Endocrine traits of polycystic ovary syndrome in prenatally androgenized female Sprague-Dawley rats. Endocr J 2010; 57: 201-9. [ Links ]

    14. Demissie M, Lazic M, Foecking EM, et al. Transient prenatal androgen exposure produces metabolic syndrome in adult female rats. Am J Physiol Endocrinol Metab 2008; 295: E262-8. [ Links ]

    15. Amalfi S, Velez L, Heber F, et al. Prenatal hyperandrogenization induces metabolic and endocrine alterations which depend on the levels of testosterone. PloS One 2012; 7: e37658. [ Links ]

    16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502. [ Links ]

    17. Corbould A. Chronic testosterone induces delective insuline resistance in subcutaneos adipocytes of women. J Endocrinol 2007; 192: 585-94. [ Links ]

    18. Austin MA, King MC, Vranizan KM, et al. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990; 80: 495-506. [ Links ]

    19. Rizzo M, Berneis K. Low- density lipoprotein size and cardiovascular risk assessment. QJM 2006; 99: 1-14. [ Links ]

    20. Ibañez L, Valls C, Potau N, et al. Polycystic ovary syndrome after precocious pubarche: ontogeny of the low-birthweight effect. Clin Endocrinol 2001; 55: 667-72. [ Links ]

    21. Kimm H, Lee SW, Lee HS, et al. Associations between lipid measures and metabolic syndrome, insulin resistance and adiponectin. - Usefulness of lipid ratios in Korean men and women. Circ J 2010; 74: 931-7. [ Links ]

    22. Wierzbicki AS, Clarke RE, Viljoen A, Mikhailidis DP. Triglycerides: a case for treatment? Curr Opin Cardiol 2012; 398: 398-404. [ Links ]

    23. Rizzo M, Longo RA, Guastella E, et al. Assessing cardiovascular risk in Mediterranean women with polycystic ovary syndrome. J Endocrinol Invest 2011; 34: 422-6. [ Links ]

    1. Charles CA, Gafni A, Whelan T. Decision-making in the physician-patient encounter: revisiting the shared treatment decision-making model. Soc Sci Med 1999; 49: 651-61. [ Links ]

    2. Charles CA, Whelan T, Gafni A, Willan A, Farell S. Shared treatment decision making: what does it mean to physicians? J Gen Clin Oncol 2003; 21: 932-6. [ Links ]

    3. Frosch D, Kaplan R. Shared decision-making in clinical medicine: past research and future directions. Am J Prev Med 1999; 17: 285-94. [ Links ]

    4. Stewart MA. Effective physician-patient communication and health outcomes: a review. Can Med Assoc J 1995; 152: 1423-33. [ Links ]

    5. Institute of Medicine. Improving the 21st Century Health-care System. Crossing the Quality Chasm: A New Health-care System for 21st Century. Washington, DC: National Academy Press; 2001. [ Links ]

    6. Levinson W, Kao A, Kuby A, Thisted RA. Not all patients want to participate in decision making. A national study of public preferences. J Gen Intern Med 2005; 20: 531-5. [ Links ]

    7. Murtagh FEM, Thorns A. Evaluation and ethical review of a tool to explore patient preferences for information and involvement in decision-making. J Med Ethics 2006; 32: 311-5. [ Links ]

    8. Roter DL, Hall JA, Auki Y. Physician gender effects in medical communication. A meta-analytic review. JAMA 2002; 288: 756-64. [ Links ]

    9. Fiscelle K, Franks P, Gold M, Clancy C. Inequality in quality: addressing socioeconomic, racial, and ethnic disparities in health care. JAMA 2000; 283: 2579-84. [ Links ]

    10. Nayfield S, Bongiovanni G, Alcioti M, Fischer R, Bergner L. Statutory requirements for disclosure of breast cancer treatment alternatives. J Natl Cancer Inst 1994; 86: 1202-8. [ Links ]

    11. Nattinger AB, Hoffman R, Shapiro R, Gottlieb M, Goodwin J. The effect of legislative requirements on the use of breast-conserving surgery. N Engl J Med 1996; 335: 1035-40. [ Links ]

    12. NHS Centre for Reviews and Dissemination. Informing, communicating and sharing decisions with people who have cancer. Effect Health Care 2000; 6: 1-8. [ Links ]

    13. McPherson CJ, Higginson U, Hearn J. Effective methods of living information in cancer: a systematic literature review of randomized controlled trials. J Public Health Med 2001; 23: 227-34. [ Links ]

    14. Harris KA. The informational needs of patients with cancer and their families. Cancer Pract 1998; 6: 39-46. [ Links ]

    15. Eagly AH, Johannesen-Schmidt MC, van Ungen ML. Transformational, transactional, and laissez-faire leadership styles: a meta-analysis comparing women and men. Psycol Bull 2003; 129: 569-91. [ Links ]

    16. Elderkin-Thompson V, Waitzin H. Differences in clinical communication by gender. J Gen Intern Med 1999; 14: 112-21. [ Links ]

    17. Pandey S, Hart J, Tiwary S. Women's health and the Internet: understanding emerging trends and implications. Soc Sci Med 2003; 53: 179-92. [ Links ]

    18. Rosen P, Anell A, Hjortsberg C. Patient views on choice and participation in primary health care. Health Policy 2001; 55: 121-8. [ Links ]

    19. Allanan J, Cleary P, Weissman J, Epstein A. The effects of race of patients' preferentes on racial differences in access to renal transplantation. N Engl J Med 1999; 341: 1661-9. [ Links ]

    20. Einbinder L, Schulman K. The effect of race on the referral process for invasive cardiac procedures. Med Care Res Rev 2000; 57: 162-80. [ Links ]

    21. Etchason J, Armour B, Ofli E, et al. Racial and ethnic disparities in health care. JAMA 2001; 285: 883. [ Links ]

    22. Mobeireek AF, Al-Kassimi F, Al-Zahrani K, et al. Information disclosure and decision-making: the Middle East versus the Far East and the West. J Med Ethics 2008; 34: 225-9. [ Links ]

    23. Deber R, Kraetschmer N, Irving J. What role do patients wish to play in treatment decision-making? Arch Intern Med 1996; 156: 1414-20. [ Links ]

    24. Arora N, McHorney C. Patient preferences for medical decision-making: who really wants to participate? Med Care 2000; 38: 325-41. [ Links ]

    1. Wax JR, Lucas FL, Lamont M, Pinette MG, Cartin A, Blackstone J. Maternal and newborn outcomes in planned home birth vs. planned hospital births: a metaanalysis. Am J Obstet Gynecol 2010; 203: 243. [ Links ]

    2. Birthplace in England Collaborative Group. Perinatal and maternal outcomes by planned place of birth for healthy women with low risk pregnancies: the Birthplace in England National Prospective Cohort Study. Br Med J 2011; 343:d7400. [ Links ]

    3. Schroeder E, Petrou S, Patel N, et al. Cost effectiveness of alternative planned places of birth in woman at low risk of complications: evidence from the Birthplace in England National Prospective Cohort Study. Br Med J 2012; 344. [ Links ]

    4. Uranga A, Urman J, Lomuto C, et al. Guía para la atención del parto normal en maternidades centradas en la familia. Dirección Nacional de Salud Materno Infantil Ministerio de Salud, Argentina, 2004. [ Links ]

    5. En: http://www.hcdn.gov.ar/proyxml/expediente.asp?fundamentos=sinumexp=7719-D-2010; consultado 5/5/2012. [ Links ]

    6. En: http://www.perfil.com/ediciones/2011/10/edicion_613/contenidos/noticia_0056.html; consultado 15/5/2012. [ Links ]

    1. Borges JL. Funes el memorioso. En: Artificios (1944). Obras completas. Buenos Aires: Emecé, 1974. p 485-90. [ Links ]

    2. Zweig S. Buchmendel (1929). En: Calidoscopio. Traducción castellana de José Fernández Z. Barcelona: Juventud, 2004, p 193-211. [ Links ]

    3. Draaisma D. Why life speeds up as you get older. How memory shapes our past (2001). Translated from the Dutch by Arnold and Erica Pomerans. Cambridge (UK): Cambridge UP, 2004. Chapter 7. The absolute memories of Funes and Sherashevsky. p 61-72. [ Links ]

    4. Quian Quiroga R. Borges y la memoria. Buenos Aires: Sudamericana, 2011. [ Links ]

    5. Hernández R. Pehuajó: Nomenclatura de las calles. Buenos Aires: J.A. Berra, 1896, p 79-89. Biblioteca Nacional de Argentina: TES 3 A 10 4 1 02/41. En: http://www.bn.gov.ar/digitalizaciones/ficha.php?id=142; consultado el 1/1/2012. [ Links ]

    6. Kandel ER. The Molecular Biology of Memory Storage: A Dialog between Genes and Synapses (Nobel Lecture). En: http://www.nobelprize.org/nobel_prizes/medicine/laureates/2000/kandel-lecture.html; consultado el 1/1/2012. [ Links ]

    1. Sívori ML, Sáenz CB, Riva Posse C. Mortalilidad por asma y enfermedad pulmonar obstructiva crónica en Argentina en el período1980-1998. Medicina (B Aires) 2001; 61: 513-21. [ Links ]

    2. Lang A, Carlsen KH, Haaland G, et al. Severe asthma in childhood: assessed in 10 year olds in a birth cohort study. Allergy 2008; 63: 1054-60. [ Links ]

    3. Pearce N, Ait-Khaled N, Beasley R, et al. Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 2007; 62: 758-66. [ Links ]

    4. Neffen H, Fritscher C, Schacht FC, et al. Asthma control in Latin America: the Asthma Insights and Reality in Latin America (AIRLA) survey. Rev Panam Salud Publica 2005; 17: 191-7. [ Links ]

    5. Bousquet J, Mantzouranis E, Cruz AA, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010; 126: 926-38. [ Links ]

    6. Brand PL, Baraldi E, Bisgaard H, et al. Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach. Eur Respir J 2008; 32: 1096-110. [ Links ]

    7. Marcone DN, Ricarte C, Videla C, et al. Rinovirus. Frecuencia en niños con infección respiratoria aguda, no internados. Medicina (B Aires) 2012; 72: 28-32. [ Links ]

    8. Taylor DR, Bateman ED, Boulet LP, et al. A new perspective on concepts of asthma severity and control. Eur Respir J 2008; 32: 545-54. [ Links ]

    9. Barton CA, McKenzie DP, Walters EH, Abramson MJ. Interactions between psychosocial problems and management of asthma: who is at risk of dying? J Asthma 2005; 42: 249-56. [ Links ]

    10. Fleming L, Wilson N, Regamey N, Bush A. Are inflammatory phenotypes in children with severe asthma stable? Eur Respir J 2007; 30: 483S. [ Links ]

    11. Mauad T, Poon AH, Hamid Q. Pathology, inflammation and cytokines of severe asthma. Eur Respir Mon 2011; 51: 97-106. [ Links ]

    12. Navarro Merino M, Andrés Martín A, Asensio de la Cruz O, García García ML, Liñán Cortes S, Villa Asensi JR. Guía de diagnóstico y tratamiento del asma de difícil control en niños. An Pediatr (Barc) 2009; 71: 548-67. [ Links ]

    14. Konradsen JR, Nordlund B, Lidegran M, et al. Problematic severe asthma: a proposed approach to identifying children who are severely resistant to therapy. Pediatr Allergy Immunol 2011; 22: 9-18. [ Links ]

    15. Lodrup Carlsen KC, Hedlin G, Bush A, et al. Assessment of problematic severe asthma in children. Eur Respir J 2011; 37: 432-40. [ Links ]

    16. Saglani S, Papaioannou G, Khoo L, et al. Can HRCT be used as a marker of airway remodelling in children with difficult asthma? Respir Res 2006; 7: 46. [ Links ]

    17. Liu AH, Zeiger R, Sorkness C, et al. Development and cross-sectional validation of the Childhood Asthma Control Test. J Allergy Clin Immunol 2007; 119: 817-25. [ Links ]

    18. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14: 902-7. [ Links ]

    19. Bossley CJ, Saglani S, Kavanagh C, et al. Corticosteroid responsiveness and clinical characteristics in childhood difficult asthma. Eur Respir J 2009; 34: 1052-9. [ Links ]

    20. British Thoracic Society, Scottish Intercollegiate Guidelines Network, British Guideline on the Management of Asthma. Thorax 2008; 63: Suppl. 4, iv1-iv121. [ Links ]

    21. Roncoroni AJ. Relación entre asma, atopía, IgE e hiperreactividad bronquial. Medicina (B Aires) 1998; 58: 243-6. [ Links ]

    22. Denning DW, O'Driscoll BR, Hogaboam CM, Bowyer P, Niven RM. The link between fungi and severe asthma: a summary of the evidence. Eur Respir J 2006; 27: 615-26. [ Links ]

    23. Langley SJ, Goldthorpe S, Craven M, Woodcock A, Custovic A. Relationship between exposure to domestic allergens and bronchial hyperresponsiveness in non-sensitised, atopic asthmatic subjects. Thorax 2005; 60: 17-21. [ Links ]

    24. Chinn S, Heinrich J, Anto JM, et al. Bronchial responsiveness in atopic adults increases with exposure to cat allergen. Am J Respir Crit Care Med 2007; 176: 20-6. [ Links ]

    25. Bush RK. Indoor allergens, environmental avoidance, and allergic respiratory disease. Allergy Asthma Proc 2008; 29: 575-9. [ Links ]

    26. Gotzsche PC, Johansen HK. House dust mite control measures for asthma: systematic review. Allergy 2008; 63: 646-59. [ Links ]

    27. de Vries MP, van den Bemt L, Aretz K, et al. House dust mite allergen avoidance and self-management in allergic patients with asthma: randomised controlled trial. Br J Gen Pract 2007; 57: 184-90. [ Links ]

    28. van den Bemt L, de Vries MP, Cloosterman S, et al. Influence of house dust mite impermeable covers on health-related quality of life of adult patients with asthma: results of a randomized clinical trial. J Asthma 2007; 44: 843-8. [ Links ]

    29. McKinley L, Alcorn JF, Peterson A, et al. TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J Immunol 2008; 181: 4089-97. [ Links ]

    30. De Boeck K, Moens M, Van Der Aa N, Meersman A, Schuddinck L, Proesmans M. 'Difficult asthma': can symptoms be controlled in a structured environment? Pediatr Pulmonol 2009; 44: 743-8. [ Links ]

    31. Hamouda S, Karila C, Connault T, Scheinmann P, de Blic J. Allergic rhinitis in children with asthma: a questionnaire-based study. Clin Exp Allergy 2008; 38: 761-6. [ Links ]

    32. Kang HY, Park CS, Bang HR, Sazonov V, Kim CJ. Effect of allergic rhinitis on the use and cost of health services by children with asthma. Yonsei Med J 2008; 49: 521-9. [ Links ]

    33. Taramarcaz P, Gibson PG. Intranasal corticosteroids for asthma control in people with coexisting asthma and rhinitis. Cochrane Database Syst Rev 2003; 4: CD003570. [ Links ]

    34. James JM. Respiratory manifestations of food allergy. Pediatrics 2003; 111: 1625-30. [ Links ]

    35. Sicherer SH, Furlong TJ, Munoz-Furlong A, Burks AW, Sampson HA. A voluntary registry for peanut and tree nut allergy: characteristics of the first 5149 registrants. J Allergy Clin Immunol 2001; 108: 128-32. [ Links ]

    36. de Groot EP, Duiverman EJ, Brand PL. Comorbidities of asthma during childhood: possibly important, yet poorly studied. Eur Respir J 2010; 36: 671-8. [ Links ]

    37. Kopel SJ, Klein RB. Childhood asthma and obesity. Med Health R I 2008; 91: 161-4. [ Links ]

    38. Scholtens S, Wijga AH, Seidell JC, et al. Overweight and changes in weight status during childhood in relation to asthma symptoms at 8 years of age. J Allergy Clin Immunol 2009; 123:1312-8 e2. [ Links ]

    39. Tolia V, Vandenplas Y. Systematic review: the extra-oesophageal symptoms of gastro-oesophageal reflux disease in children. Aliment Pharmacol Ther 2009; 29: 258-72. [ Links ]

    40. Gustafsson PM, Kjellman NI, Tibbling L. Oesophageal function and symptoms in moderate and severe asthma. Acta Paediatr Scand 1986; 75: 729-36. [ Links ]

    41. Gustafsson PM, Kjellman NI, Tibbling L. Bronchial asthma and acid reflux into the distal and proximal oesophagus. Arch Dis Child 1990; 65: 1255-8. [ Links ]

    42. Kenn K, Balkissoon R. Vocal cord dysfunction: what do we know? Eur Respir J 2011; 37: 194-200. [ Links ]

    43. Strunk RC, Mrazek DA, Fuhrmann GS, LaBrecque JF. Physiologic and psychological characteristics associated with deaths due to asthma in childhood. A case-controlled study. JAMA 1985; 254: 1193-8. [ Links ]

    44. Bergstrom SE, Boman G, Eriksson L, et al. Asthma mortality among Swedish children and young adults, a 10-year study. Respir Med 2008; 102: 1335-41. [ Links ]

    45. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2009. Gig Harbor WA. Medical Communications Resources, Inc., 2009. [ Links ]

    46. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma - Summary Report 2007. J Allergy Clin Immunol 2007; 120:S94-S138. [ Links ]

    47. Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J 2002; 19: 246-51. [ Links ]

    48. Thompson J, Irvine T, Grathwohl K, Roth B. Misuse of metered-dose inhalers in hospitalized patients. Chest 1994; 105: 715-7. [ Links ]

    49. Bracken M, Fleming L, Hall P, et al. The importance of nurse-led home visits in the assessment of children with problematic asthma. Arch Dis Child 2009; 94: 780-4. [ Links ]

    50. Holgate ST, Djukanovic R, Casale T, Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy 2005; 35: 408-16. [ Links ]

    51. Chand HS, Schuyler M, Joste N, et al. Anti-IgE therapy results in decreased myeloid dendritic cells in asthmatic airways. J Allergy Clin Immunol 2010; 125: 1157-8 e5. [ Links ]

    52. Oliver JM, Tarleton CA, Gilmartin L, et al. Reduced FcepsilonRI- mediated release of asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy. Int Arch Allergy Immunol 2009; 151: 275-84. [ Links ]

    53. Kraft S, Kinet JP. New developments in FcepsilonRI regulation, function and